clarithromycin has been researched along with s 1743 in 111 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 40 (36.04) | 29.6817 |
| 2010's | 56 (50.45) | 24.3611 |
| 2020's | 15 (13.51) | 2.80 |
| Authors | Studies |
|---|---|
| Cockeram, A; De Argila, CM; Delchier, JC; Göthe, L; Hasselgren, G; Labenz, J; Lauritsen, K; Lind, T; Sinclair, P; Stubberöd, A; Treichel, HC; Veldhuyzen Van Zanten, S; Wrangstadh, M | 1 |
| Fennerty, MB; Laine, L; Levine, JG; Osato, M; Probst, P; Suchower, L; Sugg, J | 1 |
| Bartuzi, Z; Dite, P; Hasselgren, G; Kleczkowski, D; Kryszewski, A; Larkö, A; Rudzinski, J; Tulassay, Z; Wrangstadh, M | 1 |
| Kas'ianenko, VI; Vasil'ev, IuV | 1 |
| Boon, YH; Cheng, CS; Chian, LC; Chiu, TC; Kaushik, S; Vu, C | 1 |
| Go, MF | 1 |
| Vasil'ev, IuV | 1 |
| Bokhart, GH; Jones, RJ; Sipe, BE | 1 |
| Lee, J; Machado, S; Veldhuyzen Van Zanten, S | 1 |
| Bästlein, E; Bayerdörffer, E; Buchner, M; Ebert, S; Haferland, C; Kirsch, C; Lehn, N; Miehlke, S; Neumeyer, M; Schneider-Brachert, W; Stolte, M; Vieth, M | 1 |
| Gisbert, JP; Pajares, JM | 1 |
| Chen, TW; Cheng, HC; Hunag, SF; Kao, AW; Lu, CC; Sheu, BS; Wu, JJ | 1 |
| Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Chen, YH; Li, HY; Wang, H; Wang, WM | 1 |
| Domínguez-Martín, A; Domínguez-Muñoz, A; Gisbert, JL; Gisbert, JP; Marcos, S | 1 |
| Pan, Y; Xiao, SD; Zhang, L; Zheng, Q | 1 |
| Chen, JL; Chen, WC; Cheng, JS; Hsu, PI; Lai, KH; Lin, CK; Lo, CC; Lo, GH; Tsay, FW; Tseng, HH; Wu, CJ; Yamaoka, Y; Yu, HC | 1 |
| Antos, D; Bästlein, E; Bayerdörffer, E; Buchner, M; Haferland, C; Hänel, C; Lehn, N; Meier, E; Schneider-Brachert, W; Stolte, M; Trump, F | 1 |
| Hassan, C; Morini, S; Panarese, A; Piglionica, D; Scaccianoce, G; Zullo, A | 1 |
| Andersson, T; Hassan-Alin, M; Liljeblad, M; Niazi, M; Persson, BA; Röhss, K | 1 |
| Aragona, G; Benedetti, E; Cavallaro, L; Cavestro, GM; Chilovi, F; Comparato, G; Dal Bó, N; De Bastiani, R; Di Mario, F; Fedrizzi, F; Franceschi, M; Franzè, A; Iori, V; Leandro, G; Maino, M; Marcon, V; Marin, R; Monica, F; Olivieri, P; Orzès, N; Piazzi, L; Pilotto, A; Rugge, M; Salvat, MH; Tafner, G; Valiante, F; Vecchiati, U | 1 |
| Cammarota, G; Candelli, M; Cazzato, A; Finizio, R; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Lauritano, EC; Nista, EC; Ojetti, V; Santoro, M; Zocco, MA | 1 |
| Ferrara, EC; Manes, G; Porro, GB | 1 |
| Bästlein, E; Bayerdörffer, E; Hansky, K; Jacobs, E; Kirsch, C; Kuhlisch, E; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Schneider-Brachert, W; Stolte, M | 1 |
| Alberer, M; Antos, D; Arenz, T; Buderus, S; Kappler, M; Koletzko, S; Rüssmann, H | 1 |
| Cammarota, G; Candelli, M; Cremonini, F; Finizio, R; Gasbarrini, A; Gasbarrini, G; Nista, EC; Ojetti, V; Spada, C; Zocco, MA | 1 |
| Chen, A; Hsu, PI; Lai, KH; Lo, GH; Tsay, FW; Tseng, HH; Wang, WM; Wu, CJ; Wu, DC; Wu, IC; Wu, JY | 1 |
| Bellini, M; Ciancia, E; Costa, F; Cristiani, F; de Bortoli, N; Leonardi, G; Marchi, S; Merlo, A; Mumolo, MG; Ricchiuti, A; Rossi, M; Santi, S | 1 |
| Tang, Y; Wen, FQ; Xiang, L; Zuo, WH | 1 |
| Chen, TA; Chuah, SK; Hsu, PI; Lai, KH; Lin, WS; Lo, GH; Peng, NJ; Tsay, FW; Tseng, HH; Wu, CJ | 1 |
| Bair, MJ; Chang, WH; Chen, JJ; Hsu, PI; Kuo, FC; Lu, CY; Wang, TE; Wang, WM; Wu, DC; Wu, IC; Wu, JY; Yu, FJ | 1 |
| Cho, YK; Choi, HS; Hwang, SJ; Jeon, WK; Kim, BI; Kim, HJ; Park, DI; Park, JS; Sohn, CI | 1 |
| Bästlein, E; Haferland, C; Jebens, C; Kirsch, C; Knoth, H; Kuhlisch, E; Lehn, N; Madisch, A; Miehlke, S; Morgner, A; Schneider-Brachert, W; Stolte, M; Zekorn, C | 1 |
| Cakal, B; Kiliç, ZM; Köksal, AS; Kuran, S; Nadir, I; Ozin, YO; Sahin, B | 1 |
| Butruk, E; Dite, P; Eklund, S; Engstrand, L; Gottlow, M; Malfertheiner, P; Nagy, P; Sjölund, M; Stolte, M; Tchernev, K; Tulassay, Z; Wong, BC; Wrangstadh, M | 1 |
| Chang, IJ; Jung, HC; Kang, JM; Kim, JS; Kim, N; Lee, DH; Park, YS; Song, IS | 1 |
| Dragomir, D; Hurduc, V; Plesca, D; Sajin, M; Vandenplas, Y | 1 |
| Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
| de Boer, WA; Janssen, MJ; Schrauwen, RW | 1 |
| But, D; Chan, CK; Chan, FS; Chan, P; Cheung, TK; Chu, KM; Gu, Q; Hsu, A; Hung, IF; Leung, S; Seto, WK; Tong, TS; Wong, BC; Wong, SY | 1 |
| Andrei, F; Grasso, E; Lionetti, R; Pallone, F; Paoluzi, OA; Ranaldi, R; Stroppa, I; Tosti, C; Visconti, E | 1 |
| Butruk, E; Dítê, P; Eklund, S; Engstrand, L; Gottlow, M; Herszényi, L; Malfertheiner, P; Nagy, P; Stolte, M; Tchernev, K; Tulassay, Z; Wong, BC; Wrangstadh, M | 1 |
| Abbas, Z; Abid, S; Jafri, W; Khalid, A; Khan, R; Naz, S; Yakoob, J | 1 |
| Chan, AK; Chan, FK; Chau, TS; Lee, KK; Lee, VW; Ling, TK; Waye, MM | 1 |
| Chang, JJ; Chang, LC; Chen, LW; Chien, RN; Fang, KM | 1 |
| Ahmed, MR; Youssef, TF | 1 |
| Boyanova, L; Cabrita, AM; de Carvalho, JN; Gonçalves, TM; Medeiros, JA; Pereira, AM; Pereira, MI | 1 |
| Fragou, P; Georgopoulos, S; Karatapanis, S; Laudi, F; Lisgos, P; Papantoniou, N; Papastergiou, V; Skorda, L; Spiliadi, C; Xirouchakis, E | 1 |
| Georgopoulos, S; Karatapanis, S; Laoudi, F; Lisgos, P; Papantoniou, N; Papastergiou, V; Spiliadi, C; Xirouchakis, E | 1 |
| Ashida, C; Higashida, A; Kuwada, T; Mamori, S; Mitsuoka, T; Senda, E; Suga, Y; Taki, M; Yamada, H | 1 |
| Caulet-Maugendre, S; Delaval, P; Desrues, B; Guillot, S; Jouneau, S; Kerjouan, M; Meunier, C | 1 |
| Georgopoulos, SD; Laoudi, F; Martinez-Gonzalez, B; Mentis, AF; Sgouras, DN; Spiliadi, C; Xirouchakis, E | 1 |
| Ben-Dor, D; Delgado, JS; Landa, E | 1 |
| But, DY; Hsu, AS; Hung, IF; Lam, FY; Leung, WK; Liu, KS; Seto, WK; Tong, T; Wong, SY | 1 |
| Cho, KB; Jang, BI; Jeon, SW; Jung, JT; Jung, MK; Jung, YS; Kim, ES; Kim, EY; Kim, KO; Kim, WJ; Kwon, JG; Lee, SH; Oh, MJ; Park, CS; Park, KS; Yang, CH | 1 |
| Graham, DY; Hsu, PI; Wang, WM; Wu, DC; Wu, JY | 1 |
| Mengnan, Z; Wei, Z; Wen, G; Yali, Z; Ying, L | 1 |
| Chen, M; He, L; Hou, X; Li, Z; Lin, S; Song, Z; Zhang, J; Zhou, L | 1 |
| Egawa, S; Fukui, H; Ichiba, M; Iijima, H; Inoue, A; Ishihara, R; Kishida, O; Kobayashi, I; Komori, M; Nishida, T; Ogawa, H; Oshita, M; Takeda, A; Takehara, T; Tanimura, H; Tsuji, S; Tsujii, M; Tsutsui, S; Uenoyama, N; Yasunaga, Y; Yoshio, T; Yura, M; Zushi, S | 1 |
| Azmin, S; Hashim, H; Ibrahim, NM; Manaf, MR; Razlan, H; Tan, HJ; Yahya, NW | 1 |
| Angueira, T; Ariño, I; Balboa, A; Barrio, J; Bermejo, F; Botargues-Bote, JM; Gisbert, JP; Gomez-Camarero, J; Gomez-Rodriguez, BJ; Herranz-Bachiller, MT; Huerta, A; Lucendo, AJ; Martin-Noguerol, E; McNicholl, AG; Modolell, I; Molina-Infante, J; O'Morain, C; Perez-Aisa, A; Rodriguez-Tellez, M | 1 |
| Cho, KB; Heo, J; Jang, BI; Jeon, SW; Jung, JT; Kim, HS; Kwon, JG; Lee, DW; Lee, SH; Park, JB; Park, KS; Yang, CH | 1 |
| Chiou, SS; Chiu, CH; Chiu, YC; Chuah, SK; Hu, ML; Hu, TH; Kuo, CH; Kuo, CM; Kuo, YH; Lee, CH; Liang, CM; Lu, LS; Tai, WC; Wu, KL; Yen, YH | 1 |
| Dechsukhum, C; Kaewpitoon, N; Kaewpitoon, S; Leeanansaksiri, W; Loyd, RA; Matrakool, L; Panpimanmas, S; Tongtawee, T | 1 |
| Georgopoulos, SD; Karatapanis, S; Papastergiou, V | 1 |
| Chen, DF; Han, R; Lan, CH; Li, CX; Liao, ST; Wang, CH; Yang, J; Yang, YY | 1 |
| Bhatt, NR; Bhatt, R; Kakked, GA | 1 |
| Bai, P; He, L; Song, Z; Xue, Y; Zhang, J; Zhou, L | 1 |
| Niv, Y | 1 |
| Forte, A; Jeverica, S; Šeruga, M; Stefanovič, M; Tepeš, B; Vujasinović, M | 1 |
| Chen, JH; Chua, CS; Hsu, YH; Huang, SY; Lee, HC; Liu, YH; Yang, KC | 1 |
| Amorena, E; Campillo, A; Kutz, M; LaIglesia, M; Ostiz, M | 1 |
| Georgopoulos, SD; Grivas, E; Kasapidis, P; Laoudi, F; Martinez-Gonzales, B; Mentis, A; Michopoulos, S; Petraki, K; Sgouras, D; Sotiropoulou, M; Spiliadi, C; Xirouchakis, E; Zampeli, E; Zografos, K | 1 |
| Alvaro, D; Bellesia, A; De Francesco, V; Hassan, C; Ridola, L; Vaira, D; Zullo, A | 1 |
| Boemi, M; Bonazzi, P; Bonfigli, AR; Brandoni, G; Ceriello, A; Festa, R; Genovese, S; Olivieri, F; Spazzafumo, L; Testa, R | 1 |
| Hayakawa, Y; Hirata, Y; Koike, K; Sakitani, K; Serizawa, T; Shichijo, S; Suzuki, N; Yamada, A | 1 |
| Eguchi, T; Fujita, M; Fukuchi, T; Hashimura, H; Kanamori, A; Kano, C; Koizumi, A; Matsumoto, K; Momose, K; Okada, A; Shimoyama, K; Tsujimae, M; Yamashita, H | 1 |
| Chen, H; Hao, B; Su, J; Zhang, G; Zhang, W; Zhou, X | 1 |
| Chiba, H; Chinda, D; Fukuda, S; Komai, K; Matsuzaka, M; Saito, Y; Sasaki, Y; Sawada, Y; Shimoyama, T | 1 |
| Chen, Y; Ke, L; Li, CJ; Liang, J; Ni, Z; Shang, L; Shi, YQ; Zhang, D; Zhang, LH; Zhu, SH | 1 |
| Bellesia, A; De Francesco, V; Palma, R; Panetta, C; Pontone, S; Serviddio, G; Zullo, A | 1 |
| Hong, JB; Lu, NH; Luo, LY; Shu, X; Xie, C; Xie, Y; Ye, JF; Zhu, Y; Zhu, ZH | 1 |
| Adachi, T; Asakuma, Y; Kamata, K; Kashida, H; Komeda, Y; Kono, M; Kudo, M; Matsui, S; Minaga, K; Nagai, T; Nishida, N; Okamoto, A; Okamoto, K; Sakurai, T; Takenaka, M; Watanabe, T; Yamada, M; Yamao, K | 1 |
| Furuta, T; Horio, Y; Ichikawa, H; Kagami, T; Kato, A; Ohashi, N; Sahara, S; Sakao, Y; Sugimoto, K; Sugimoto, M; Yasuda, H | 1 |
| Fiorini, G; Gatta, L; Pavoni, M; Saracino, IM; Vaira, D; Zullo, A | 1 |
| Chen, Q; Liang, X; Liu, W; Long, X; Lu, H; Yu, L | 1 |
| Bair, MJ; Chang, CC; Chang, CY; Chen, CC; Chen, MJ; Chen, PY; El-Omar, EM; Fang, YJ; Hsu, WF; Hsu, YC; Lee, JY; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Wu, MS; Yang, TH | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Shahbazi, S; Vahdat Shariatpanahi, Z | 1 |
| Chao, SH; Ding, SZ; Lan, L; Li, J; Li, YX; Wang, XM; Yang, TT; Yi, DM; Zhang, HH; Zhang, YR; Zhang, YW; Zhou, YL | 1 |
| Chen, Y; Li, J; Liu, L; Lu, B; Wang, J | 1 |
| Chen, DF; Fan, L; Lan, CH; Wang, TY; Wang, XW; Yang, J; Zhang, Y; Zhu, YJ | 1 |
| Kim, N; Yoon, K | 1 |
| Amato, A; De Francesco, V; Fiorini, G; Mogavero, G; Monica, F; Portincasa, P; Scaccianoce, G; Urban, F; Vaira, D; Vassallo, R; Zullo, A | 1 |
| Chen, Q; Chen, Y; Gao, H; Graham, DY; Ji, Y; Li, D; Liang, X; Liu, M; Liu, W; Long, X; Lu, H; Song, Y; Sun, Y; Xu, B; Xu, G; Yu, L; Zhang, W; Zhao, Y | 1 |
| Liu, W; Liu, Y; Wang, X; Wang, Y; Zhu, J | 1 |
| Jin, Z; Li, Y; Lin, D; Lin, L; Meng, F; Pan, J; Shi, Z; Wu, J; Yang, N; Zhang, J; Zhou, Q | 1 |
| Pan, L; Tang, G; Tang, Y; Wei, Z; Zhou, S; Zhu, H | 1 |
| Niu, Z; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L | 1 |
| Cho, SJ; Choi, J; Chung, H; Chung, SJ; Kim, JL; Kim, SG; Lee, A | 1 |
| Bozic, J; Kardum, G; Mestrovic, A; Pavicic Ivelja, M; Perkovic, N; Puljiz, Z; Tonkic, A; Vukovic, J | 1 |
| Chen, Y; Deng, X; Hou, X; Shi, Z; Ye, H; Yuan, H; Zhang, X | 1 |
| Cha, JM; Jeon, JW; Kwak, MS; Yoon, JY | 1 |
| Daugule, I; Leja, M; Lielause, A; Park, JY; Paršutins, S; Poļaka, I; Rūdule, A; Sjomina, O; Stonāns, I; Vangravs, R | 1 |
| Ahmad, A; Alamri, AS; Basheeruddin Asdaq, SM; Di Cerbo, A; Farid, A; Ghazanfar, S; Israr, M; Khan, KA; Muzammal, M; Pugliese, N | 1 |
| Gou, LZ; Han, TY; Li, XL; Lin, YM; Wang, C; Xu, HM; Yi, GR; Yu, Y; Yun, JW; Zhang, DK | 1 |
| He, XJ; Huang, XY; Li, DL; Li, DZ; Liu, G; Wang, W; Wang, XL | 1 |
| Bair, MJ; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chiu, MC; Chou, CK; El-Omar, EM; Fang, YJ; Hsu, YC; Hu, WH; Jiang, XT; Kuo, CC; Lee, JY; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tsai, MH; Tseng, CH; Wu, MS; Yang, TH; Yu, CC | 1 |
| Ellakany, WI; Ghazy, RM; Ismail, A; Kamal, A; Sherief, D | 1 |
| Chen, JN; Ding, ZH; Huang, Y; Liang, X; Lu, H; Luo, LS; Zhang, W | 1 |
| Guo, Y; Hu, J; Lan, CH; Liu, HN; Liu, HQ; Liu, YX; Mei, H; Shi, Q; Su, NY; Wang, XW | 1 |
5 review(s) available for clarithromycin and s 1743
| Article | Year |
|---|---|
Treatment and management of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Cardiovascular Diseases; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Rabeprazole; Stomach Neoplasms; Treatment Outcome | 2002 |
Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2005 |
Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era.
Topics: Anti-Bacterial Agents; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Probiotics; Proton Pump Inhibitors; Stomach Neoplasms | 2015 |
Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Proton Pump Inhibitors; Ranitidine; Tetracycline | 2016 |
81 trial(s) available for clarithromycin and s 1743
| Article | Year |
|---|---|
One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Stereoisomerism | 2000 |
Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials.
Topics: Adult; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillin Resistance; Penicillins; Prospective Studies; Protein Synthesis Inhibitors; Proton Pump Inhibitors | 2000 |
One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Time Factors; Treatment Outcome | 2001 |
[Efficacy of the one week treatment with esomeprazole (nexium), clarythromycin, and amoxycillin of duodenal ulcer associated with Helicobacter pylori].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Helicobacter pylori; Humans; Prospective Studies | 2002 |
[Pharmacoeconomic aspects of the 1-week eradication treatment of duodenal ulcer associated with Helicobacter pylori].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Analysis; Drug Administration Schedule; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillins | 2002 |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance; Treatment Outcome | 2003 |
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Patient Compliance; Treatment Outcome | 2003 |
Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Gastric Mucosa; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mixed Function Oxygenases; Omeprazole; Risk | 2005 |
[Comparison of esomeprazole- and omeprazole-based triple therapy regimens for duodenal ulcer with Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 2005 |
Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Ulcer; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole | 2005 |
Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors | 2005 |
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Patient Compliance; Peptic Ulcer; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2005 |
7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Prospective Studies; Treatment Outcome | 2006 |
Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Tinidazole; Treatment Outcome | 2006 |
Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Antagonism; Esomeprazole; Female; Half-Life; Helicobacter Infections; Humans; Male; Mixed Function Oxygenases | 2006 |
Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Cattle; Chi-Square Distribution; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Male; Middle Aged; Prospective Studies; Tinidazole; Treatment Outcome | 2006 |
Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pilot Projects; Rifamycins; Rifaximin; Treatment Outcome | 2006 |
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cross-Over Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Rifabutin; Treatment Outcome | 2006 |
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Esomeprazole; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Prospective Studies; Treatment Outcome | 2006 |
Randomized comparison of two rescue therapies for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Tetracycline | 2006 |
Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactoferrin; Male; Middle Aged; Probiotics; Prospective Studies; Treatment Outcome | 2007 |
[Different courses of esomeprazole-based triple therapy for Helicobactor pylori infection in children].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male | 2007 |
High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Pilot Projects; Prospective Studies; Treatment Outcome | 2007 |
Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Patient Compliance; Proton Pump Inhibitors; Rabeprazole | 2007 |
Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole | 2007 |
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adult; Aged; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Mixed Function Oxygenases; Moxifloxacin; Polymorphism, Restriction Fragment Length; Prospective Studies; Quinolines; Rifabutin | 2008 |
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Middle Aged; Moxifloxacin; Pilot Projects; Prospective Studies; Quinolines; Ranitidine; Treatment Outcome; Young Adult | 2008 |
Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Esomeprazole; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Secondary Prevention; Severity of Illness Index; Stomach Ulcer; Treatment Outcome; Young Adult | 2008 |
A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Probiotics; Prospective Studies; Proton Pump Inhibitors; Saccharomyces | 2009 |
Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin | 2009 |
Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Tinidazole; Treatment Outcome; Young Adult | 2010 |
Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-positive patients with gastric ulcers.
Topics: Amoxicillin; Clarithromycin; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Stomach Ulcer; Treatment Outcome | 2010 |
Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in Helicobacter pylori eradication in Hong Kong non-ulcer dyspepsia Chinese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Breath Tests; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Male; Middle Aged; Mutation; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Rabeprazole; Urea | 2010 |
Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line Helicobacter pylori eradication: a prospective randomised study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Treatment Outcome | 2010 |
Treatment of clinically diagnosed laryngopharyngeal reflux disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Egypt; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Laryngopharyngeal Reflux; Laryngoscopy; Male | 2010 |
Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Combined Modality Therapy; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus acidophilus; Male; Microbial Sensitivity Tests; Middle Aged; Peptic Ulcer; Probiotics; Single-Blind Method; Treatment Outcome; Urea; Young Adult | 2011 |
Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Esomeprazole; Female; Greece; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Prospective Studies | 2012 |
Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome; Urea | 2013 |
Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Young Adult | 2013 |
Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Breath Tests; China; Clarithromycin; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Organometallic Compounds; Prospective Studies; Tetracycline; Treatment Outcome | 2014 |
Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2014 |
A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; China; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Tinidazole; Treatment Outcome; Young Adult | 2014 |
Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Humans; Japan; Lansoprazole; Male; Middle Aged; Prospective Studies; Time Factors; Young Adult | 2014 |
Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antiparkinson Agents; Breath Tests; Clarithromycin; Comorbidity; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Young Adult | 2015 |
Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2015 |
Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Combinations; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged | 2015 |
Effect of Pretreatment with Lactobacillus delbrueckii and Streptococcus thermophillus on Tailored Triple Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus delbrueckii; Male; Metronidazole; Middle Aged; Probiotics; Prognosis; Prospective Studies; Streptococcus; Young Adult | 2015 |
Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Health Knowledge, Attitudes, Practice; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Patient Satisfaction; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Telephone; Time Factors; Treatment Outcome | 2015 |
Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Stomach Ulcer; Treatment Outcome; Young Adult | 2016 |
Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Pyloric Antrum; Urea | 2016 |
Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Italy; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Time Factors; Treatment Outcome | 2016 |
Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biomarkers; Blood Glucose; Clarithromycin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Homeostasis; Host-Pathogen Interactions; Humans; Inflammation Mediators; Insulin; Insulin Resistance; Italy; Male; Middle Aged; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2016 |
Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2017 |
Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Asian People; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Esomeprazole; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2017 |
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Topics: Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Berberine; Bismuth; Body Mass Index; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Severity of Illness Index; Sex Factors | 2017 |
Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors | 2018 |
Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies | 2017 |
Efficacy of Reduced Dosage of Amoxicillin in an Eradication Therapy for Helicobacter pylori Infection in Patients on Hemodialysis: A Randomized Controlled Trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Levofloxacin; Male; Middle Aged; Prevalence; Renal Dialysis; Treatment Outcome | 2018 |
Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2018 |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacteriological Techniques; Breath Tests; Clarithromycin; Clinical Decision-Making; Doxycycline; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Predictive Value of Tests; Proton Pump Inhibitors; Taiwan; Tetracycline; Time Factors; Treatment Outcome | 2018 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.
Topics: Adult; Amoxicillin; Clarithromycin; Dysgeusia; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Patient Compliance; Tinidazole; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
Comparison the cost-efficacy of furazolidone-based versus clarithromycin-based quadruple therapy in initial treatment of Helicobacter pylori infection in a variable clarithromycin drug-resistant region, a single-center, prospective, randomized, open-label
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Treatment Outcome | 2019 |
Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Outcome | 2019 |
Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Costs; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Treatment Outcome; Urea | 2019 |
Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Time Factors; Tinidazole; Treatment Outcome | 2019 |
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2019 |
Effects of addition of probiotic and/or bismuth to triple therapy of H. pylori and analysis of genetic variation of 23S rRNA gene between patients with clarithromycin sensitivity and resistance.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Asian People; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Esomeprazole; Female; Gene Frequency; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Polymorphism, Single Nucleotide; Probiotics; RNA, Ribosomal, 23S; Treatment Outcome | 2019 |
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2020 |
A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2020 |
Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Republic of Korea; RNA, Ribosomal, 23S; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2020 |
Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Croatia; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2020 |
Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Proton Pump Inhibitors; Treatment Outcome | 2021 |
Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of Helicobacter pylori Eradication: A Prospective, Randomized, Controlled and Open-Label Study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Treatment Failure; Treatment Outcome | 2021 |
Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome | 2022 |
High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomised controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Nausea; Pectins; Proton Pump Inhibitors; Treatment Outcome | 2023 |
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Australia; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; RNA, Ribosomal, 16S; Young Adult | 2023 |
Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; COVID-19; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Pandemics; Proton Pump Inhibitors; Treatment Outcome | 2023 |
A randomized superiority clinical trial: metronidazole improved the efficacy of high-dose dual therapy in Helicobacter pylori rescue treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Treatment Outcome | 2023 |
25 other study(ies) available for clarithromycin and s 1743
| Article | Year |
|---|---|
One week regimen of esomeprazole based triple therapy is sufficient for duodenal ulcer healing and Helicobacter pylori eradication in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Prospective Studies; Treatment Outcome | 2002 |
Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction.
Topics: Atorvastatin; Clarithromycin; Drug Interactions; Esomeprazole; Female; Heart Block; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Rhabdomyolysis | 2003 |
Eradication of Helicobacter pylori and dosages of esomeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2006 |
Esomeprazole-based 1-week triple therapy directed by susceptibility testing for eradication of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Patient Compliance; Prospective Studies; Treatment Outcome | 2006 |
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Treatment Outcome | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication.
Topics: Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Proton Pump Inhibitors | 2009 |
Risk factors associated with Helicobacter pylori infection treatment failure in a high prevalence area.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pakistan; Point Mutation; Prevalence; Risk Factors; RNA, Bacterial; RNA, Ribosomal, 23S; Treatment Failure; Urea; Virulence Factors; Young Adult | 2011 |
Effectiveness of esomeprazole-based triple therapy of H. pylori in young patients in Japan.
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Cohort Studies; Drug Therapy, Combination; Esomeprazole; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Metronidazole; Middle Aged | 2013 |
Clarithromycin stops lung function decline in airway-centered interstitial fibrosis.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Enzyme Inhibitors; Esomeprazole; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Prednisolone; Pulmonary Fibrosis; Radiography; Respiratory Function Tests; Treatment Failure | 2013 |
Granulomatous gastritis and Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Esomeprazole; Female; Gastritis; Granuloma; Helicobacter Infections; Helicobacter pylori; Humans; Symptom Assessment; Treatment Outcome | 2013 |
[Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedule; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Logistic Models; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Republic of Korea; Retrospective Studies; Treatment Outcome | 2014 |
Rome III criteria cannot distinguish patients with chronic gastritis from those functional dyspepsia patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Neutrophil Infiltration | 2014 |
Pneumobilia with gastric outlet obstruction.
Topics: Amoxicillin; Anti-Bacterial Agents; Biliary Tract Diseases; Clarithromycin; Esomeprazole; Gastric Bypass; Gastric Outlet Obstruction; Humans; Intestinal Fistula; Male; Middle Aged; Peptic Ulcer; Postprandial Period; Proton Pump Inhibitors; Treatment Outcome; Vomiting; Weight Loss | 2015 |
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Outcome | 2016 |
The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bacterial Adhesion; Blueberry Plants; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Grape Seed Extract; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged | 2016 |
[10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Spain; Stomach Ulcer | 2016 |
Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2016 |
A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2016 |
Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies | 2017 |
Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Time Factors; Tinidazole; Treatment Outcome | 2018 |
[Eradication Rates of 10-day Sequential Therapy for
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prospective Studies; Republic of Korea; Tertiary Care Centers; Treatment Outcome | 2019 |
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2020 |
Preparation and Characterization of Controlled-Release Floating Bilayer Tablets of Esomeprazole and Clarithromycin.
Topics: Clarithromycin; Delayed-Action Preparations; Esomeprazole; Excipients; Helicobacter Infections; Helicobacter pylori; Humans; Solubility; Tablets | 2022 |
Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome; Young Adult | 2023 |